Cited by 584Psychedelics and Drug StudiesSubstance Abuse Treatment and OutcomesNeurotransmitter Receptor Influence on Behavior

The DOI matches its Crossref record; 39 of the 39 references it cites were found in a registry or an index.

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Krebs, Teri S, Johansen, Pål-Ørjan·2012·Journal of Psychopharmacology

DOI 10.1177/0269881112439253

Open this paper in CoChat — free account

Abstract

Assessments of lysergic acid diethylamide (LSD) in the treatment of alcoholism have not been based on quantitative meta-analysis. Hence, we performed a meta-analysis of randomized controlled trials in order to evaluate the clinical efficacy of LSD in the treatment of alcoholism. Two reviewers independently extracted the data, pooling the effects using odds ratios (ORs) by a generic inverse variance, random effects model. We identified six eligible trials, including 536 participants. There was evidence for a beneficial effect of LSD on alcohol misuse (OR, 1.96; 95% CI, 1.36–2.84; p = 0.0003). Between-trial heterogeneity for the treatment effects was negligible (I 2 = 0%). Secondary outcomes, risk of bias and limitations are discussed. A single dose of LSD, in the context of various alcoholism treatment programs, is associated with a decrease in alcohol misuse.

Integrity signals

Registry

Crossref · 10.1177/0269881112439253

Cites

39 of 39 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Global burden of disease and injury and economic cost attributable to alcohol use and alcohol-use disorders
Rehm, J., Mathers, C., Popova, S., Thavorncharoensap, M., Teerawattananon, Y., & Patra, J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60746-7 · Cited by 3,870
Untitled work
(2008) · Cited by 3,790
Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance
Griffiths, R. R., Richards, W. A., McCann, U., & Jesse, R. (2006) · Psychopharmacology · doi:10.1007/s00213-006-0457-5 · Cited by 1,684 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
Drug harms in the UK: a multicriteria decision analysis
Nutt, D. J., King, L. A., & Phillips, L. D. (2010) · The Lancet · doi:10.1016/s0140-6736(10)61462-6 · Cited by 1,681
Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Grob, C. S., Danforth, A. L., Chopra, G. S., Hagerty, M., McKay, C. R., Halberstadt, A. L., & Greer, G. R. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2010.116 · Cited by 1,206
Human hallucinogen research: guidelines for safety
Johnson, M., Richards, W., & Griffiths, R. (2008) · Journal of Psychopharmacology · doi:10.1177/0269881108093587 · Cited by 1,203
Opioid antagonists for alcohol dependence
Srisurapanont, M., & Jarusuraisin, N. (2002) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd001867 · Cited by 762
Alcohol-use disorders
Schuckit, M. A. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60009-x · Cited by 715
Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies
Studerus, E., Kometer, M., Hasler, F., & Vollenweider, F. X. (2011) · Journal of Psychopharmacology · doi:10.1177/0269881110382466 · Cited by 532 · cited 2×
“, 2002; McGlothlin, 1964), and in clinical studies the effects of psychedelics are often regarded as highly valued and meaningful (Griffiths et al., 2006; Grob et al., 2011; Studerus et al., 2011).”
Background
The pharmacology of lysergic acid diethylamide: A review
Passie, T., Halpern, J. H., Stichtenoth, D. O., Emrich, H. M., & Hintzen, A. (2008) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2008.00059.x · Cited by 455

Show all 39 references

Research works printed but not linked: 6

Ables MF, 1967, Highlights of the twelfth annual conference in cooperative studies in psychiatry
Ables MF, 1970, Group treatment of chronic alcoholism with LSD-25: study II. Newsletter for research in psychology, United States Veterans Administration, 12, 17
American Psychiatric Association (1952) Diagnostic and Statistical Manual for Mental Disorders. First Edition. Washington, DC: American Psychiatric Association, 39.
Kurland AA, 1971, Advances in neuropsychopharmacology: proceedings of the 7th congress of the collegium internationale neuro-psychopharmacologicum, 361
Rösner S, 2010, Cochrane Database Syst Rev, 9, CD004332
Rösner S, 2010, Cochrane Database Syst Rev, 12, CD001867

Sorted by citations

Items 301–400 of 584

Therapeutic Applications of Ayahuasca and Other Sacred Medicines
Winkelman, M. (2013) · Springer eBooks · doi:10.1007/978-3-642-40426-9_1 · Cited by 11
Emerging Psychedelic-Assisted Therapies: Implications for Nursing Practice
Denis-Lalonde, D., & Estefan, A. (2020) · Journal of Mental Health and Addiction Nursing · doi:10.22374/jmhan.v4i1.40 · Cited by 11
Back to the future: A return to psychedelic treatment models for addiction
Hendricks, P. S. (2014) · Journal of Psychopharmacology · doi:10.1177/0269881114550935 · Cited by 11
Le traitement médiatique du LSD en France en 1966 : de la panique morale à la fin des études cliniques
Dubus, Z. (2022) · Cygne noir · doi:10.7202/1091460ar · Cited by 10
Classic psychedelics as therapeutics for psychiatric disorders
Nichols, C. D., & Hendricks, P. S. (2020) · Handbook of behavioral neuroscience · doi:10.1016/b978-0-444-64125-0.00049-9 · Cited by 11
5-HT2A and 5-HT2C receptors as potential targets for the treatment of nicotine use and dependence
Higgins, G. A., & Sellers, E. M. (2021) · Progress in brain research · doi:10.1016/bs.pbr.2021.01.007 · Cited by 10
Classic psychedelics and the treatment for alcoholism
Lodetti, G., de Bitencourt, R. M., & Rico, E. P. (2024) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2024.111129 · Cited by 11
Rational Suicide in the Elderly
Balasubramaniam, M., & McCue, R. E. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6 · Cited by 10
‘Wearing down of the self’: Embodiment, writing and disruptions of identity in transformational festival fieldwork
Ruane, D. (2017) · Methodological Innovations · doi:10.1177/2059799117720611 · Cited by 10
Psilocybin as a Novel Pharmacotherapy for Treatment-Refractory Anorexia Nervosa
Rodan, S.-C., Aouad, P., McGregor, I. S., & Maguire, S. (2021) · OBM Neurobiology · doi:10.21926/obm.neurobiol.2102102 · Cited by 12
A Century of Homeopaths
Davidson, J. R. T. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0527-0 · Cited by 10
Psychotherapie mit adjuvanter Gabe von serotonergen psychoaktiven Substanzen – Möglichkeiten und Hindernisse
Majić, T., Jungaberle, H., Schmidt, T. T., Zeuch, A., Hermle, L., & Gallinat, J. (2017) · Fortschritte der Neurologie · Psychiatrie · doi:10.1055/s-0043-103085 · Cited by 10
Probing the functional magnetic resonance imaging response to psilocybin in functional neurological disorder (PsiFUND): study protocol
Butler, M., Bird, C., Maggio, C., Durden, A., Modlin, N. L., Campbell‐Coker, K., Edwards, M. J., Pick, S., Millman, L. S. M., Lowery, E., et al. (2024) · Wellcome Open Research · doi:10.12688/wellcomeopenres.22543.1 · Cited by 9
Psychoactive substances for the treatment of neuropsychiatric disorders
Zhen, Z., Sun, X., Yuan, S., & Zhang, J. (2024) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2024.104193 · Cited by 11
Mortality risk among people receiving acute hospital care for hallucinogen use compared with the general population
Myran, D. T., Xiao, J., Fabiano, N., Pugliese, M., Kaster, T. S., Rosenblat, J. D., Husain, M. I., Fiedorowicz, J. G., Wong, S., Tanuseputro, P., et al. (2025) · Canadian Medical Association Journal · doi:10.1503/cmaj.241191 · Cited by 9
Psychedelics: The pathway to implementation in the European healthcare systems
Gründer, G., Mertens, L. J., Spangemacher, M., Meyer‐Lindenberg, A., & Jungaberle, H. (2025) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2025.11.007 · Cited by 10
Psychedelic medicine: mechanisms, evidence, and translation to practice
Jacobs, E., Zahid, Z., Hinkle, J. T., Nayak, S. M., & Yaden, D. B. (2026) · BMJ · doi:10.1136/bmj-2024-081723 · Cited by 9
Recreation and Realization: Reported Motivations of Use Among Persons Who Consume Psychedelics in Non-Clinical Settings
Dollar, C. B. (2021) · doi:10.21428/88de04a1.cb6fef95 · Cited by 10
Evidence versus expectancy: the development of psilocybin therapy
Rucker, J. (2023) · BJPsych Bulletin · doi:10.1192/bjb.2023.28 · Cited by 9
Hallucinogenic potential: a review of psychoplastogens for the treatment of opioid use disorder
Hornick, M. G., & Stefanski, A. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1221719 · Cited by 9
LSD use in the United States: Examining user demographics and their evolution from 2015–2019
Weleff, J., Anand, A., Dewey, E. N., & Barnett, B. S. (2024) · Journal of Psychedelic Studies · doi:10.1556/2054.2024.00309 · Cited by 8
Emerging medications and pharmacological treatment approaches for substance use disorders
Raymond, J. S., Athanasopoulos, A. G., Badolato, C. J., Doolan, T. M., Scicluna, R. L., Everett, N. A., Bowen, M. T., & James, M. H. (2024) · Pharmacology Biochemistry and Behavior · doi:10.1016/j.pbb.2024.173952 · Cited by 9
Tū Wairua: Development of an Indigenous Rongoā Māori approach to healing with psilocybin containing mushrooms
Hodge, A.-L., Forsyth, A., Noorani, T. N., Muthukumaraswamy, S. D., Rolleston, A. K., & McHugh, P. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00436 · Cited by 9
Changing your mind: neuroplastic mechanisms underlying the therapeutic effect of psychedelics in depression, PTSD, and addiction
Palhas, M. L. C., Corne, R., & Mongeau, R. (2025) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2025.111533 · Cited by 10
Psilocybin in the Treatment of Cocaine Use Disorder
Hendricks, P. S., Lappan, S. N., Shelton, R. C., Lahti, A. C., Cropsey, K. L., Johnson, M. W., Bradley, M. K., Simonsson, O., Davis, L. L., Grossman, D. H., et al. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2026.11029 · Cited by 9
Hallucinogen Use and Misuse in Older Adults
Redden, W. M., Paracha, S.-U.-R., & Sheheryar, Q. (2021) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2021.07.007 · Cited by 8
EMBARK Psychedelic Therapy for Depression
Brennan, B., & Belser, A. (2024) · doi:10.1093/9780197762622.001.0001 · Cited by 8
Effects of a Single Dose of Ayahuasca in College Students With Harmful Alcohol Use
Rodrigues, L. S., Reis, J. A. S., Rossi, G. N., Guerra, L. T. L., Maekawa, R. M., Osório, F. D. L., Bouso, J. C., Santos, F. P., Paranhos, B. A. P. B., Yonamine, M., et al. (2024) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000001872 · Cited by 9
Perceptions of safety, subjective effects, and beliefs about the clinical utility of lysergic acid diethylamide in healthy participants within a novel intervention paradigm: Qualitative results from a proof-of-concept study
Hendricks, P. S., Copes, H., Family, N., Williams, L. T. J., Luke, D. P., & Raz, S. (2022) · Journal of Psychopharmacology · doi:10.1177/02698811211055855 · Cited by 9
What can we learn from the history of research on psychedelic drugs in the addictions?
Hall, W., & Farrell, M. (2021) · Addiction · doi:10.1111/add.15560 · Cited by 8
5‐Methoxy‐ N , N ‐dimethyltryptamine (5‐MeO‐DMT) for alcohol use disorder: An open‐label, phase 2, proof‐of‐concept, clinical trial
Marsden, J., Kelleher, M., Dunbar, F., Ermakova, A. O., Mitcheson, L., Roberts, C., Rucker, J., Scott, G., Saeger, I., Small, F., et al. (2025) · Addiction · doi:10.1111/add.70260 · Cited by 7
Efficacy and Safety of Psychedelics in Mental Disorder Cases: An Umbrella Review of Meta-Analyses of Randomized Controlled Trials
Dominiak, M., Gędek, A., Modrzejewski, S., Permoda-Pachuta, A., & Antosik-Wójcińska, A. Z. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm15010253 · Cited by 7
Perspective: Can psychedelic-assisted therapy be a promising aid in compulsive sexual behavior disorder treatment?
Wizła, M., Kraus, S. W., & Lewczuk, K. (2022) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2022.152303 · Cited by 9
A roadmap for psychedelic pharmacy in Canada: A proposed policy and operations approach for controlled access to select psychedelics for treatment of mental illness
Brandt, J. (2023) · Drug Science Policy and Law · doi:10.1177/20503245231170340 · Cited by 9
Psychedelic-assisted therapy for people with gambling disorder?
Romero, P., Czakó, A., van den Brink, W., & Demetrovics, Z. (2024) · Journal of Behavioral Addictions · doi:10.1556/2006.2024.00004 · Cited by 10
Psychedelics and substance use disorder treatment
DuPont, C. M., & Johnson, M. W. (2025) · International review of neurobiology · doi:10.1016/bs.irn.2025.03.005 · Cited by 8
A rare case of physical dependence with psychedelic LSD - A case report
Modak, T., Bhad, R., & Rao, R. (2019) · Journal of Substance Use · doi:10.1080/14659891.2019.1581286 · Cited by 7
In vivo PET Imaging of [11C]CIMBI-5, a 5-HT2AR Agonist Radiotracer in Nonhuman Primates
Prabhakaran, J., DeLorenzo, C., Zanderigo, F., Knudsen, G. M., Gilling, N., Pratap, M., Jorgensen, M. J., Daunais, J., Kaplan, J. R., Parsey, R. V., et al. (2019) · Journal of Pharmacy & Pharmaceutical Sciences · doi:10.18433/jpps30329 · Cited by 7
Ayahuasca and Psychotherapy: Beyond Integration
Diament, M., Gomes, B., & Tófoli, L. F. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_4 · Cited by 7
Therapeutic Use of Hallucinogens
Wiltenburg, V. D., Prado, D. D. R., & Mendes, F. (2021) · Springer eBooks · doi:10.1007/978-3-030-62855-0_35 · Cited by 1
Psychedelics in the Treatment of Substance Use Disorders
Barnett, B. S., & Weleff, J. (2022) · Psychiatric Annals · doi:10.3928/00485713-20220804-01 · Cited by 7
Dosing and Therapeutic Conduct in Administration Sessions in Substance-Assisted Psychotherapy: A Systematized Review
Thal, S. B., Wieberneit, M., Sharbanee, J. M., Skeffington, P., Bruno, R., Wenge, T., & Bright, S. J. (2023) · Journal of Humanistic Psychology · doi:10.1177/00221678231168516 · Cited by 9
The substanceou l’histoire mouvementée du LSD
Beck, F., & Bonnet, N. (2013) · médecine/sciences · doi:10.1051/medsci/2013294018 · Cited by 7
Psychedelics and Hallucinogens in Psychiatry: Finding New Pharmacological Targets
de Sousa, T. R., Rema, J., Machado, S. E. D. C., & Novais, F. (2021) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026621666211201145800 · Cited by 7
Moderating factors in psilocybin-assisted treatment affecting mood and personality: A naturalistic, open-label investigation
Irrmischer, M., Puxty, D. J., Yıldırım, B. O., Deijen, J. B., & Engelbregt, H. (2025) · Psychopharmacology · doi:10.1007/s00213-024-06733-3 · Cited by 7
Significant Psychedelic Experiences Evaluated for Mystical Characteristics Associated with Cannabis Use Reduction and Psychological Flexibility Improvement: A Naturalistic Cross-Sectional Retrospective Survey
Roméo, B., Kervadec, E., Fauvel, B., Strika-Bruneau, L., Amirouche, A., Verroust, V., Piolino, P., & Benyamina, A. (2024) · Journal of Psychoactive Drugs · doi:10.1080/02791072.2024.2375720 · Cited by 6
Efficacy and Safety of LSD in the treatment of mental and substance use disorders: A systematic review of randomized controlled trials
Fernandes-Nascimento, M. H., Weber, P., & Negrão, A. B. (2025) · Psychiatry Research · doi:10.1016/j.psychres.2025.116622 · Cited by 6
Psychedelic therapy in the Czech Republic: A theoretical concept or a realistic goal?
Postránecká, Z., Vejmola, Č., & Tylš, F. (2019) · Journal of Psychedelic Studies · doi:10.1556/2054.2019.003 · Cited by 7
New Insights Into the Clinical and Nonclinical Effects of Psychedelic Substances
Forstmann, M., & Sagioglou, C. (2021) · European Psychologist · doi:10.1027/1016-9040/a000447 · Cited by 7
Views on Using Psychoactive Substances to Self-Manage Functional Neurological Disorder: Online Patient Survey Results
Butler, M., Seynaeve, M., Bradley‐Westguard, A., Bao, J., Crawshaw, A. A., Pick, S., Edwards, M. J., Nicholson, T. R., & Rucker, J. (2022) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.21080213 · Cited by 6
3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs
López‐Arnau, R., Camarasa, J., Carbó, M., Nadal‐Gratacós, N., Puigseslloses, P., Espinosa‐Velasco, M., Urquizu, E., Escubedo, E., & Pubill, D. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2022.990405 · Cited by 6
No time to lose: the current state of research in rapid-acting psychotherapeutics
Gordon, J. A., Volkow, N. D., & Koob, G. F. (2023) · Neuropsychopharmacology · doi:10.1038/s41386-023-01627-y · Cited by 6
Can Neuroscience Improve Addiction Treatment and Policies?
Nutt, D., & McLellan, A. T. (2013) · Public health reviews · doi:10.1007/bf03391704 · Cited by 6
User perceptions of mental health consequences of hallucinogen use in self-identified spiritual contexts
Johnstad, P. G. (2015) · Nordic Studies on Alcohol and Drugs · doi:10.1515/nsad-2015-0053 · Cited by 11
Hallucinogens
Hanks, J. B., & González‐Maeso, J. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-800212-4.00076-5 · Cited by 6
Perspectives on Healing and Recovery from Addiction with Ayahuasca-Based Therapy Among Members of an Indigenous Community in Canada
Argento, E., Capler, R., THOMAS, G. W., Lucas, P., & Tupper, K. W. (2021) · Springer eBooks · doi:10.1007/978-3-030-55688-4_10 · Cited by 6
Single-dose psilocybin promotes cell-type-specific changes of neurons in the orbitofrontal cortex
Huang, Z., Wei, X., Wang, Y., Tian, J., Dong, J., Liang, B., Lu, L., & Zhang, W. (2026) · Neurotherapeutics · doi:10.1016/j.neurot.2026.e00841 · Cited by 8
Effects of psychedelic, DOI, on nucleus accumbens dopamine signaling to predictable rewards and cues in rats
Martin, D. A., Delgado, A. M., & Calu, D. J. (2024) · Neuropsychopharmacology · doi:10.1038/s41386-024-01912-4 · Cited by 9
The Psychedelic Renaissance: A Catholic Perspective
Carroll, T. (2024) · The Linacre Quarterly · doi:10.1177/00243639241274818 · Cited by 5
Impact of psychedelics on craving in addiction: A systematic review
Chapron, S., Bonazzi, G., Lodovico, L. D., de Ternay, J., Landmann, C., Nourredine, M., Salvo, F., Sessa, B., Das, R., Rolland, B., et al. (2025) · Journal of Psychopharmacology · doi:10.1177/02698811241308613 · Cited by 6
Using Psychedelics in Clinical Practice: Comparing Therapeutic Uses and Potential Harms
Tariq, R. (2022) · Current Clinical Pharmacology · doi:10.2174/2772432817666220321142707 · Cited by 5
Psychedelic Therapies at the Crossroads of Trauma and Substance Use: Historical Perspectives and Future Directions, Taking a Lead From New Mexico
Bhatt, S. R., Armstrong, M., Parker, T., Maviglia, M. A., Kass, R., Leeman, L. M., Romo, P., & Ziedonis, D. M. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.905753 · Cited by 8
Therapeutic Potential of Psychedelic Compounds for Substance Use Disorders
Valdez, T., Patel, V., Senesombath, N., Hatahet-Donovan, Z., & Hornick, M. G. (2024) · Pharmaceuticals · doi:10.3390/ph17111484 · Cited by 5
Clinical Research on Lysergic Acid Diethylamide (LSD) in Psychiatry and Neuroscience
Omidian, H., & Omidian, A. (2025) · Pharmaceuticals · doi:10.3390/ph18040499 · Cited by 6
Psychedelics for Alcohol Use Disorder: A Narrative Review with Candidate Mechanisms of Action
Miller, E. A., Capone, C., Eaton, E. M., Swift, R. M., & Haass‐Koffler, C. L. (2025) · CNS Drugs · doi:10.1007/s40263-025-01199-z · Cited by 6
Brain scans reveal how LSD affects consciousness
Cormier, Z. (2016) · Nature · doi:10.1038/nature.2016.19727 · Cited by 5
Who Is Keeping Tabs? LSD Lessons from the Past for the Future
Dyck, E. (2018) · Springer eBooks · doi:10.1007/978-3-319-76720-8_1 · Cited by 5
Public Health and the Harm Reduction Approach to Illegal Psychoactive Substances ☆
Emerson, B., & Haden, M. (2018) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.66208-6 · Cited by 5
Histoire du LSD. De l’ergot de seigle à l’utilisation thérapeutique
Gicquel, T., Lepage, S., & Morel, I. (2015) · La Presse Médicale · doi:10.1016/j.lpm.2015.04.033 · Cited by 5
Psilocybin’s acute and persistent brain effects: a precision imaging drug trial
Subramanian, S., Reneau, T. R., Perry, D., Chacko, R. V., Laumann, T. O., Flavin, K., Horan, C., Schweiger, J. A., Metcalf, N. V., Lenze, E. J., et al. (2025) · Scientific Data · doi:10.1038/s41597-025-05189-0 · Cited by 6
Psychoanalyst attitudes towards psychedelic-assisted therapy
Kraiem, E., Diener, M., Guss, J., Mavrides, L., & Saban, S. (2025) · Drugs Education Prevention and Policy · doi:10.1080/09687637.2024.2359444 · Cited by 4
A Systematic Review and Meta-Analysis Investigating the Efficacy of Various Psychedelic Drugs for the Treatment of Substance Use Disorder
Keighley, E. E., Bedewy, D., Hamza, E. A., Nalla, S., & Moustafa, A. A. (2025) · Healthcare · doi:10.3390/healthcare13212668 · Cited by 6
The immunomodulatory effects of psychedelics in Alzheimer’s disease-related dementia
Hosseini, A. M., Khaleghzadeh‐Ahangar, H., & Rahimi, A. (2024) · Neuroscience · doi:10.1016/j.neuroscience.2024.11.062 · Cited by 4
LSD: Mechanisms and relevance to the treatment of depression
Bouloufa, A., Delcourte, S., Delannay, T., Rovera, R., Lau, T., Moulédous, L., Dkhissi‐Benyahya, O., Guiard, B. P., & Haddjeri, N. (2025) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2025.106407 · Cited by 4
Addiction of Hallucinogens, Dissociatives, Designer Drugs and “Legal Highs”: Update on Potential Therapeutic Use
Farré, M., Papaseit, E., Fonseca, F., & Torrens, M. (2020) · Springer eBooks · doi:10.1007/978-3-030-36391-8_19 · Cited by 5
Offering a putative neurobiological “dopamine homeostatic” solution to overcome the perils of the reward deficiency syndrome pandemic: emergence of “precision behavioral management”
Blum, K., Dennen, C. A., Baron, D. A., Thanos, P. K., & Badgaiyan, R. D. (2022) · Annals of Translational Medicine · doi:10.21037/atm-2022-67 · Cited by 4
Invited Expert Opinion- Bio-informatic and Limitation Di-rectives to Help Adopt Ge-netic Addiction Risk Screening and Identify Preaddictive Reward Dysregulation: Re-quired Analytic Evidence to Induce Dopamine Homeo-statsis
Blum, K., Gold, M. S., Cadet, J. L., Lewis, M., McLaughlin, T., Braverman, E. R., Elman, I., Carney, B., Cortese, R., Abijo, T., et al. (2023) · Medical Research Archives · doi:10.18103/mra.v11i8.4211 · Cited by 6
Towards a New Materialism in Psychedelic Studies
Oostveen, D. F. (2023) · Deleuze and Guattari Studies · doi:10.3366/dlgs.2023.0530 · Cited by 4
Ética en el uso de psicodélicos: la definición de las drogas ilícitas bajo la óptica de la bioética crítica
Liblik, S. A., da Cunha, T. R., Liblik, C. S. D. F. K., Biscioni, D. N., & Girardi, D. R. (2024) · Salud Colectiva · doi:10.18294/sc.2024.4630 · Cited by 4
[Effective interventions in the problematic use of alcohol and other drugs].
Lefio, L. Á., Villarroel, S. R., Rebolledo, C., Zamorano, P., & Rivas, K. (2013) · PubMed · Cited by 4
The current state of ayahuasca research in animal models: A systematic reviewPreprint
Daldegan‐Bueno, D., Simionato, N. M., Favaro, V. M., & Maia, L. O. (2022) · doi:10.31234/osf.io/7s3b8 · Cited by 4
Psychedelics for substance use disorders: are women being addressed? A scoping review
Nigri, A. W., de Arruda, I. F., Maia, C. G. F., Tófoli, L. F., & Carezzato, F. (2025) · International Journal of Drug Policy · doi:10.1016/j.drugpo.2025.104960 · Cited by 3
How to set up a psychedelic study: Unique considerations for research involving human participants
Glennon, M. J., Bird, C., Yadav, P., Kleine, P., Suseelan, S., Boman-Markaki, C., Kotoula, V., Butler, M., Leech, R., Roseman, L., et al. (2026) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2026.106657 · Cited by 5
Beyond prohibition: A public health analysis of naturalistic psychedelic use
Haden, M., Paschall, S. A., & Woods, B. (2025) · Journal of Psychedelic Studies · doi:10.1556/2054.2025.00450 · Cited by 3
Dancing the Wild Divine: Drums, Drugs, and Individuation
Moores, D. J. (2020) · Journal of Jungian Scholarly Studies · doi:10.29173/jjs126s · Cited by 4
Licit use of illicit drugs for treating depression: the pill and the process
Pacheco, A. T., & Moghaddam, B. (2024) · Journal of Clinical Investigation · doi:10.1172/jci180217 · Cited by 3
Treating Alcohol Use Disorder With Hallucinogens—Renewed Interest After a 50-Year Hiatus
Kranzler, H. R., & Hartwell, E. E. (2022) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2022.2029 · Cited by 3
Introduction to Substance Use Disorders for the Eating Disorder Specialist
Dennis, A. B., & Pryor, T. L. (2014) · Springer eBooks · doi:10.1007/978-3-642-45378-6_12 · Cited by 3
Saints Run Mad 2.0: Further Deliberations on Recovery from Addictions Through a Transpersonal Lens
Eng, P. A. (2015) · Pastoral Psychology · doi:10.1007/s11089-015-0678-9 · Cited by 3
Classic Psychedelics and Rational Suicide in the Elderly: Exploring the Potential Utility of a Reemerging Treatment Paradigm
Hendricks, P. S., & Grob, C. S. (2016) · Springer eBooks · doi:10.1007/978-3-319-32672-6_14 · Cited by 3
“Go Ask Alice”: The Case for Researching Schedule I Drugs
Iserson, K. V. (2018) · Cambridge Quarterly of Healthcare Ethics · doi:10.1017/s0963180118000518 · Cited by 3
Hallucinogens
Chan, R. H. A., & Mendelson, J. E. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-418679-8.00017-4 · Cited by 3
Structure–Activity Relationship and Evaluation of Phenethylamine and Tryptamine Derivatives for Affinity towards 5-Hydroxytryptamine Type 2A Receptor
Wang, S., Zhu, A., Paudel, S., Jang, C., Lee, Y. S., & Kim, K. (2022) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2022.096 · Cited by 3
Less Is More: Finding the Right Dose
Davidson, J. (2014) · Springer eBooks · doi:10.1007/978-1-4939-0527-0_16 · Cited by 3
État des lieux de la recherche sur les capacités thérapeutiques des « substances hallucinogènes » au 21 e siècle
Sueur, C. (2018) · Psychotropes · doi:10.3917/psyt.233.0125 · Cited by 5
LSD helps to treat alcoholism
Frood, A. (2012) · Nature · doi:10.1038/nature.2012.10200 · Cited by 3
Public Health and the Harm Reduction Approach to Illegal Psychoactive Substances
Emerson, B., & Haden, M. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-803678-5.00510-5 · Cited by 5
Psychedelics and schizophrenia: A mystery in history
Haden, M., Woods, B., & Paschall, S. A. (2023) · Journal of Psychedelic Studies · doi:10.1556/2054.2023.00277 · Cited by 6
Mimosa tenuiflora (Willd.) Poir e Anadenanthera colubrina como alternativas no tratamento da adicção às drogas
de Sousa, P. C. M., de Sousa, I. N. A., Leite, L. L. L., Oliveira, A. L. O., Souza, K. A. D. S., Soares, J. D. S., Viana, M. D. R., & do Amaral, M. P. D. M. (2021) · Research Society and Development · doi:10.33448/rsd-v10i4.14251 · Cited by 3
Uso ritual de alucinógenos y medicina psicodélica: Articulaciones alrededor del uso clínico de la ayahuasca en Brasil
Oña, G. (2023) · Quaderns de l'Institut Català d'Antropologia · doi:10.56247/qua.401 · Cited by 3

Authors: Krebs, T. S., & Johansen, P.-Ø.
Affiliations: Harvard University (US)
Venue: Journal of Psychopharmacology
Publisher: SAGE Publications
Published: 2012-03-08
Volume: 26
Issue: 7
Pages: 994-1002
ISSN: 0269-8811 (ISSN-L)
1461-7285
DOI: 10.1177/0269881112439253
OpenAlex: W1973613743
Cited by: 583
References: 39
Citations by year: 2026: 39 · 2025: 55 · 2024: 67 · 2023: 63 · 2022: 59 · 2021: 52 · 2020: 55 · 2019: 25 · 2018: 34 · 2017: 29 · 2016: 31 · 2015: 25 · 2014: 23 · 2013: 19 · 2012: 6
FWCI: 3.40
Type: journal article
Language: en
Open access: closed
Licence: journals.sagepub.com/page/policies/text-and-data-mining-license (tdm)
Locations: Journal of Psychopharmacology (publishedVersion)
PubMed (publishedVersion)
Topics: Social Sciences › Psychology › Clinical Psychology › Psychedelics and Drug Studies
Health Sciences › Medicine › Epidemiology › Substance Abuse Treatment and Outcomes
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
Keywords: lysergic acid diethylamide, LSD, alcoholism, alcohol abuse, psychedelic therapy, alcoholism treatment, treatment efficacy
MeSH terms: Adult, Alcoholism, Combined Modality Therapy, Hallucinogens, Humans, Lysergic Acid Diethylamide, Randomized Controlled Trials as Topic, Substance Abuse Treatment Centers, Secondary Prevention

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Lysergic acid diethylamide (LSD) for alcoholism: meta-analysis of randomized controlled trials

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks